Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
12 June 2006Website:
http://www.atecspine.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:56:54 GMTDividend
Analysts recommendations
Institutional Ownership
ATEC Latest News
Alphatec (ATEC) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
24/7 Wall St. Insights With a market rotation underway, where should investors seeking opportunities in health care be looking?
Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q2 2024 Results Conference Call July 31, 2024 4:30 PM ET Company Participants Patrick Miles - Chairman and CEO Todd Koning - CFO Conference Call Participants Vik Chopra - Wells Fargo Eric Anderson - TD Cowen Matt Blackman - Stifel Drew Ranieri - Morgan Stanley Aaron Wukmir - Lake Street Capital Markets David Saxon - Needham & Co. Jason Wittes - ROTH Sean Lee - H.C. Wainwright Operator Good afternoon, everyone, and welcome to the webcast of ATEC's Second Quarter Financial Results.
Alphatec (ATEC) announces the commercial launch of its EOS Insight, an end-to-end spine surgery platform powered by standardized EOSedge scans and artificial intelligence.
Alphatec Holdings, Inc. (ATEC) Q4 2023 Earnings Call Transcript
Alphatec (ATEC) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.33 per share a year ago.
In recent years, Alphatec Holdings has outperformed expectations on a regular basis and successfully taken share in the $8 billion U.S. spinal disorder treatment market. The company is capitalizing on M&A-related disruptions at key competitors, which has created opportunities for Alphatec to grab additional market share. Persistent cash usage has resulted in substantial debt accumulation and material dilution for common shareholders, but the company appears adequately financed to reach cash flow breakeven by 2025.
Alphatec Holdings, Inc.'s focus on growth rather than improving margins raises caution for investors. Despite strong revenue growth, the company continues to experience substantial losses and slow progress on margin improvements. The recent share sales and high debt levels contribute to investor uncertainty about the company's commitment to shareholder value.
Alphatec Holdings, Inc. (NASDAQ:ATEC ) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Pat Miles - Chairman and Chief Executive Officer Todd Koning - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Matt Blackman - Stifel Matthew O'Brien - Piper Sandler Joshua Jennings - TD Cowen Drew Ranieri - Morgan Stanley Sean Lee - H.C. Wainwright Jason Wittes - ROTH Operator Good afternoon, everyone and welcome to the webcast of ATEC's Third Quarter Financial Results.
Alphatec just priced an offering of 14.3 million shares at $10.50 per share -- a more than 18% discount from yesterday's close. The offering was filed pursuant to a previously filed shelf registration statement by the company.
What type of business is Alphatec Holdings?
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
What sector is Alphatec Holdings in?
Alphatec Holdings is in the Healthcare sector
What industry is Alphatec Holdings in?
Alphatec Holdings is in the Medical Devices industry
What country is Alphatec Holdings from?
Alphatec Holdings is headquartered in United States
When did Alphatec Holdings go public?
Alphatec Holdings initial public offering (IPO) was on 12 June 2006
What is Alphatec Holdings website?
https://www.atecspine.com
Is Alphatec Holdings in the S&P 500?
No, Alphatec Holdings is not included in the S&P 500 index
Is Alphatec Holdings in the NASDAQ 100?
No, Alphatec Holdings is not included in the NASDAQ 100 index
Is Alphatec Holdings in the Dow Jones?
No, Alphatec Holdings is not included in the Dow Jones index
When was Alphatec Holdings the previous earnings report?
No data
When does Alphatec Holdings earnings report?
The next expected earnings date for Alphatec Holdings is 06 November 2024